Zymeworks Chief Scientific Officer Andrew Paul Moore Sells $1M After Modest Run-Up
Citizens Maintains Market Outperform on Zymeworks, Raises Price Target to $39
Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $44
TD Cowen Maintains Buy on Zymeworks, Raises Price Target to $39
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $36
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $56
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Zymeworks Raises FY2026 Sales Guidance from $278.000M-$292.000M to $337.000M-$351.000M vs $302.672M Est
Zymeworks Q3 EPS $2.28 Beats $2.18 Estimate, Sales $256.460M Beat $228.465M Estimate
Zymeworks (ZYME) Stock May Be Overvalued On Its New Lung Cancer Deal
Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates - Slideshow
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing Deal
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks stock surges on $813M Roche licensing deal
Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.